UK markets open in 5 minutes

Agilent Technologies, Inc. (0HAV.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
121.58-11.25 (-8.47%)
At close: 6:26PM GMT
Full screen
Previous close132.83
Open120.73
Bid0.00 x 0
Ask0.00 x 0
Day's range120.73 - 121.58
52-week range120.73 - 121.58
Volume25
Avg. volumeN/A
Market cap38.523B
Beta (5Y monthly)1.01
PE ratio (TTM)46.82
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
Press releases
  • Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
    Business Wire

    Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)

    Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab-rwlc). This announcement underscores Agilent's continuing commitment to the development of IHC-based diagnostics for cancer therapy.

  • Agilent Ranks No. 2 on Barron’s List of America’s Most Sustainable Companies
    Business Wire

    Agilent Ranks No. 2 on Barron’s List of America’s Most Sustainable Companies

    Agilent Technologies Inc. (NYSE: A) has earned the number two position on Barron’s annual list of America’s Most Sustainable Companies. The ranking marks the third straight year Agilent has been included among the top three Most Sustainable Companies. Agilent has also received the number one ranking in the life sciences industry for each of the four years the Barron’s ranking has been compiled.

  • Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies
    Business Wire

    Agilent Announces Immunoassay Kit to Detect SARS-CoV-2 Antibodies

    Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma. The kit, which marks Agilent’s entrance into SARS-CoV-2 testing in the US, has completed the notification process to FDA in accordance with Section IV.D of FDA’s "Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)". The assay is planned to be registered in other markets in 2021 including Canada, Europe, and selected Asia Pacific and Latin American countries.